

5000



525 Rec'd PCT/PTO 15 JUL 2002

#4

PATENT APPLICATION

Our File No.: 20020065.ORI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re App : James Oliver Dolly et al : July 9, 2002  
S.N. : 10/049,967 : Art Unit unknown  
Filed : February 18, 2002  
For : ISOFORMS OF SNARE MOLECULES AND THE  
USES THEREOF IN MODULATION OF  
CELLULAR EXOCYTOSIS  
-----

Hon. Commissioner of Patents and Trademarks

Washington, D.C. 20231

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER RULE 1.56

Applicant(s) herein make available to the Patent and Trademark Office a copy of Form PTO-1449 which lists the following document(s), copies of which are enclosed. This Information Disclosure Statement is being filed in accordance with the following provision(s):

- ☐ 37 CFR 1.97(b)(1) Within three months of the filing date of the national application. No fee is required.
- ☐ 37 CFR 1.97(b)(2) Within three months of the date of entry of the national stage as set forth in § 1.491 in the international application. No fee is required.
- ☒ 37 CFR 1.97(b)(3) Before the mailing date of a first Office Action on the merits. No fee is required.
- ☐ 37 CFR 1.97(c) After the periods specified in 37 CFR 1.97(b), but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.

- [ ] The undersigned hereby certifies that each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; or
- [ ] The undersigned hereby certifies that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; or
- [ ] Enclosed is a check in the amount of \$200.00 for the fee set forth in 37 CFR § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required under 37 C.F.R. 1.17, or credit any overpayment, to Deposit Account No. 08-1265. Two copies of this sheet are enclosed.
- [ ] 37 CFR 1.97(d) After the mailing date of either (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first, but before payment of the issue fee.
- [ ] Applicant(s) hereby petition the Commissioner of Patents and Trademarks to consider this information disclosure statement. Enclosed is a check in the amount of \$130.00 for the petition fee set forth in § 1.17(i)(1). The Commissioner is hereby authorized to charge any additional fees which may be required under 37 C.F.R. 1.17, or credit any overpayment, to Deposit Account No. 08-1265. Two copies of this sheet are enclosed.

The Examiner is requested to consider carefully the complete text of these documents in connection with the examination of the above-identified application in accordance with 37 CFR 1.104(a). It is requested that the documents listed on the attached Form PTO-1449 be included in the "References Cited" portion of any patent

issuing from this application (M.P.E.P. 1302.12), and that the Examiner initial and return a copy of the form to evidence consideration of the documents.

Dated: July 9, 2002

Respectfully submitted,

NIKOLAI & MERSEREAU, P.A.



C. G. Mersereau  
Attorney for Applicant(s)  
Registration No. 26,205  
900 Second Avenue South  
Suite 820  
Minneapolis, MN 55402  
Phone: 612-339-7461


#### CERTIFICATE OF MAILING

I hereby certify that the foregoing Information Disclosure Statement Under Rule 1.56, Form PTO-1449 and a copy of each cited reference to be filed in connection with application Serial No. 10/049,967 of inventors, James O. Dolly et al, filed February 18, 2002, for "ISOFORMS OF SNARE MOLECULES AND THE USES THEREOF IN MODULATION OF CELLULAR EXOCYTOSIS" are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner of Patents and Trademarks, Box DD, Washington, D.C. 20231 on July 9, 2002.



Barbara L. Davis  
Secretary to C. G. Mersereau

Date of Signature: July 9, 2002



Form PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)	Document Number 20020065.ORI	Application Number 10/049,967
	Applicant James O. Dolly et al	
	Filing Date February 18, 2002	Group Art Unit Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS


DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
					YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

	Angaut-Petit D et al, NEUROSCIENCE, Terminal Sprouting in Mouse Neuromuscular Junctions Poisoned with Botulinum Type A Toxin: Morphological and Electrophysiological Features, (1990) Vol. 37, No. 3, pp. 799-808
	Sloop et al, NEUROLOGY, Reconstituted Botulinum Toxin Type A Does Not Lose Potency in Humans if it is Refrozen or Refrigerated for 2 Weeks Before Use, Vol. 48, 1997, pp. 249-253
	T. J. Cava, EUROPEAN JOURNAL OF NEUROLOGY, Botulinum Toxin Management of Spasticity in Upper Motor Neuron Lesions, Vol. 2, 1995, pp. 57-60
	Pellizzari et al, BIOLOGICAL SCIENCE, Tetanus and Botulinum Neurotoxins: Mechanism of Action and Therapeutic Uses, Vol. 354, 1999, pp. 259-68
	Sollner et al. CELL, A Protein Assembly-Disassembly Pathway in Vitro That May Correspond to Sequential Steps of Synaptic Vesicle Docking, Activation, and Fusion, November 5, 1993, Vol. 75, pp. 409-418
	Bennett et al, SCIENCE, Syntaxin: A Synaptic Protein Implicated in Docking of Synaptic Vesicles at Presynaptic Active Zones, Vol. 257, July 10, 1992, pp. 255-259
	Trimble et al, PROC. NATL. ACAD. SCIENCE, VAMP-1: A Synaptic Vesicle-associated Integral Membrane Protein, Vol. 85, June 1988, pp. 4538-4542

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



Form PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)	Document Number 20020065.ORI	Application Number 10/049,967
	Applicant James O. Dolly et al	
	Filing Date February 18, 2002	Group Art Unit Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS


DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
					YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

	Lane et al, JOURNAL OF NEUROCHEMISTRY, <i>Characterization of the Palmitoylation Domain of SNAP-25</i> , Vol. 69, 1997, pp. 1864-1869
	de Paiva et al, PRO. NAT'L. ACAD. SCIENCE, <i>Functional Repair of Motor Endplates After Botulinum Neurotoxin Type A Poisoning: Biphasic Switch of Synaptic Activity between Nerve Sprouts and Their Parent Terminals</i> , Vol. 96, (March 1999), pp. 3200-3205
	Morgan et al, CELL & DEVELOPMENTAL BIOLOGY, <i>Common Mechanisms for Regulated Exocytosis in the Chromaffin Cell and the Synapse</i> , Vol. 8, 1997, pp. 141-149
	Shone et al, CURR TOP MICROBIOL IMMUNOL, <i>Growth of Clostridia and Preparation of Their Neurotoxins</i> , Vol. 195, (1995) pp. 143-160
	Steven P. Wilson, JOURNAL OF NEUROSCIENCE METHODS, <i>Purification of Adrenal Chromaffin Cells on Renografin Gradients</i> , Vol. 19, (1987), pp. 163-171
	Holz et al, METHODS ENZYMOL, <i>Investigation by Transient Transfection of the Effects on Regulated Exocytosis of Rab3a</i> , Vol. 257, (1995), pp. 221-231
	Smith et al, GENE, <i>Single-Step Purification of Polypeptides Expressed in Escherichia Coli as Fusions With Glutathione S-Transferase</i> , Vol. 67, 1988, pp. 31-40
	McMahon et al, NATURE, <i>Cellubrevin is a Ubiquitous Tetanus-Toxin Substrate Homologous to a Putative Synaptic Vesicle Fusion Protein</i> , Vol. 364, (1993), pp. 346-349

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



Form PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)	Document Number 20020065.ORI	Application Number 10/049,967
	Applicant James O. Dolly et al	
	Filing Date February 18, 2002	Group Art Unit Unknown

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
---------------------	-----------------	------	------	-------	----------	-------------------------------

## FOREIGN PATENT DOCUMENTS


	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

	Schechter et al, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, <i>On The Size of the Active Site in Proteases. I Papain</i> , Vol. 27, (1967), pp. 157-162
	Risinger et al, JOURNAL OF BIOLOGICAL CHEMISTRY, <i>Evolutionary Conservation of Synaptosome-associated Protein 25 kDa (SNAP-25) Shown by Drosophila and Torpedo</i> , Vol. 268, (November 15, 1993), pp. 24408-24414
	Grant et al, JOURNAL OF NEUROCHEMISTRY, <i>Differential Expression of SNAP-25 Isoforms and SNAP-23 in the Adrenal Gland</i> , Vol. 72, pp. 363-372
	Roth et al, FEBS LETT., <i>SNAP-25 is Present in a SNARE Complex in Adrenal Chromaffin Cells</i> , Vol. 351, (1994), pp. 207-210
	Eleopra et al, NEUROSCIENCE LETTERS, <i>Different Time Courses of Recovery After Poisoning with Botulinum Neurotoxin Serotypes A and E in Humans</i> , Vol. 256, (1998), pp. 135-138
	Bark et al, PROC. NAT'L ACAD. SCIENCE, <i>Differential Expression of SNAP-25 Protein Isoforms During Divergent Vesicle Fusion Event of Neural Development</i> , Vol. 92, (1998), pp. 1510-1514
	L.C. Sellin, MEDICAL BIOLOGY, <i>The Action of Botulinum Toxin at the Neuromuscular Junction</i> , Vol. 59, (1981), pp. 11-20
	Ashton et al., JOURNAL OF NEUROCHEMISTRY, <i>Microtubule-Dissociating Drugs and A23187 Reveal Differences in the Inhibition of Synaptosomal Transmitter Release by Botulinum Neurotoxins types A and B</i> , Vol. 56, (1991), pp. 827-835
	Banerjee et al, J. BIOLOGICAL CHEMISTRY, <i>SNAP-25 is Required for a Late Postdocking Step in Ca<sup>2+</sup>-dependent Exocytosis</i> , Vol. 271, (1996), pp. 20227-20230

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



Form PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)	Document Number 20020065.ORI	Application Number 10/049,967
	Applicant James O. Dolly et al	
	Filing Date February 18, 2002	Group Art Unit Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
					YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

	Cherington, M, MUSCLE & NERVE, <i>Clinical Spectrum of Botulism</i> , Vol. 21, (1998), pp. 701-710
	Gonzalo et al, MOLECULAR BIOLOGY OF THE CELL, <i>SNAP-25 Palmitoylation and Plasma Membrane Targeting Require a Functional Secretory Pathway</i> , Vol. 9, March 1999, pp. 585-597

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.